Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 9
2004 12
2005 13
2006 5
2007 10
2008 13
2009 13
2010 17
2011 20
2012 20
2013 14
2014 11
2015 22
2016 23
2017 23
2018 38
2019 32
2020 42
2021 58
2022 47
2023 59
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Results by year

Filters applied: . Clear all
Page 1
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M, Friedrich MJ, Lu KH, Vonhören D, Jansky S, Michel J, Keib A, Stange S, Hackert N, Kehl N, Hahn M, Habel A, Jung S, Jähne K, Sahm F, Betge J, Cerwenka A, Westermann F, Dreger P, Raab MS, Meindl-Beinker NM, Ebert M, Bunse L, Müller-Tidow C, Schmitt M, Platten M. Kilian M, et al. Among authors: muller tidow c. Sci Immunol. 2024 May 3;9(95):eadj7970. doi: 10.1126/sciimmunol.adj7970. Epub 2024 May 3. Sci Immunol. 2024. PMID: 38701193
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Baden D, et al. Among authors: muller tidow c. Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Online ahead of print. Haematologica. 2024. PMID: 38654660 Free article.
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: muller tidow c. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19436. Online ahead of print. Br J Haematol. 2024. PMID: 38593353
Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
Gente K, Feisst M, Marx D, Klika KD, Christopoulos P, Graf J, Will J, Luft T, Hassel JC, Müller-Tidow C, Carvalho RA, Lorenz HM, Souto-Carneiro MM. Gente K, et al. Among authors: muller tidow c. Ann Rheum Dis. 2024 Apr 1:ard-2023-224839. doi: 10.1136/ard-2023-224839. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38561219 Free article.
Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.
Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Müller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Korell F, et al. Among authors: muller tidow c. EClinicalMedicine. 2024 Feb 27;69:102504. doi: 10.1016/j.eclinm.2024.102504. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38544797 Free PMC article.
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence.
Eckardt JN, Hahn W, Röllig C, Stasik S, Platzbecker U, Müller-Tidow C, Serve H, Baldus CD, Schliemann C, Schäfer-Eckart K, Hanoun M, Kaufmann M, Burchert A, Thiede C, Schetelig J, Sedlmayr M, Bornhäuser M, Wolfien M, Middeke JM. Eckardt JN, et al. Among authors: muller tidow c. NPJ Digit Med. 2024 Mar 20;7(1):76. doi: 10.1038/s41746-024-01076-x. NPJ Digit Med. 2024. PMID: 38509224 Free PMC article.
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Felipe Fumero E, Walter C, Frenz JM, Seifert FC, Alla V, Hennig T, Angenendt L, Hartmann W, Wolf S, Serve H, Oellerich T, Lenz G, Müller-Tidow C, Schliemann C, Huber O, Dugas M, Mann M, Jayavelu AK, Mikesch JH, Arteaga MF. Felipe Fumero E, et al. Among authors: muller tidow c. Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640. Online ahead of print. Blood. 2024. PMID: 38457355 Free article.
N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia.
Peramangalam PS, Surapally S, Veltri AJ, Zheng S, Burns R, Zhu N, Rao S, Muller-Tidow C, Bushweller JH, Pulikkan JA. Peramangalam PS, et al. Among authors: muller tidow c. Sci Adv. 2024 Mar;10(9):eadh8493. doi: 10.1126/sciadv.adh8493. Epub 2024 Feb 28. Sci Adv. 2024. PMID: 38416825 Free PMC article.
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, Görner M, Kayser S, Krause S, Schliemann C, Gaska T, Kaufmann M, Chemnitz J, Schaich M, Hoellein A, Platzbecker U, Kieser M, Müller-Tidow C, Schlenk RF. Jaramillo S, et al. Among authors: muller tidow c. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284346. Online ahead of print. Haematologica. 2024. PMID: 38385304 Free article.
462 results